MoonLake Common Stock Total Equity from 2010 to 2024

MLTX Stock  USD 54.17  0.15  0.28%   
MoonLake Immunotherapeuti Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity is likely to outpace its year average in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2010-12-31
Previous Quarter
6.1 K
Current Value
6.4 K
Quarterly Volatility
2.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 K, Other Operating Expenses of 34.1 M or Total Operating Expenses of 34.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.28. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
  
Check out the analysis of MoonLake Immunotherapeuti Correlation against competitors.

Latest MoonLake Immunotherapeuti's Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of MoonLake Immunotherapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. MoonLake Immunotherapeuti's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

MoonLake Common Stock Total Equity Regression Statistics

Arithmetic Mean1,214
Geometric Mean114.99
Coefficient Of Variation200.46
Mean Deviation1,874
Median43.00
Standard Deviation2,434
Sample Variance5.9M
Range6.3K
R-Value0.70
Mean Square Error3.3M
R-Squared0.49
Significance0
Slope380.37
Total Sum of Squares82.9M

MoonLake Common Stock Total Equity History

2024 6364.73
2023 6061.65
2022 5271.0

About MoonLake Immunotherapeuti Financial Statements

MoonLake Immunotherapeuti investors use historical fundamental indicators, such as MoonLake Immunotherapeuti's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MoonLake Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity6.1 K6.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.